AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00467935
Drug: intravitreal injection Lucentis (ranibizumab)
RxNorm normalized name: Lucentis Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravitreal injection Lucentis (ranibizumab)
Trial: NCT00019864
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00019864
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00019864
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01212588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets once daily for seven days
Trial: NCT00879957
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
Trial: NCT00879957
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
Trial: NCT00742469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03327792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01173081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
Trial: NCT01356966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo pills PO BID for12 weeks
Trial: NCT03898583
Drug: Microarray patch A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microarray patch
Trial: NCT03898583
Drug: Microarray patch B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microarray patch
Trial: NCT03898583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microarray patch vehicle
Trial: NCT03898583
Drug: Daivobet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daivobet Gel
Trial: NCT04178980
Drug: Simvastatin in relapsing remitting multiple sclerosis
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
Trial: NCT01015833
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01671280
Drug: Azithromycin IV
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy.
Trial: NCT03062423
Drug: Sofodelevier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 400 mg sofosbuvir
Trial: NCT03686969
Drug: Octanorm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octanorm 0.5g/kg/week
Trial: NCT02344225
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
Trial: NCT02344225
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
Trial: NCT02344225
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
Trial: NCT01154647
Drug: 1 ml 0.9 % NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT03611426
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline solution
Trial: NCT02182349
Drug: [14C]-BI 201335 NA radiolabelled drug
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03913819
Drug: First line treatment: oral NSAID and anticholinergic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral NSAID and anticholinergic agents
Trial: NCT03913819
Drug: Second line treatment: additional treatment for pain control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin, tramadol, Lyrica
Trial: NCT03913819
Drug: Third line treatment: A course of intravesical hyaluronate will be given.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A course of intravesical hyaluronate will be given.
Trial: NCT03269214
Drug: Topical Phenytoin 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
Trial: NCT01688024
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02668146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to study subjects
Trial: NCT03312517
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive placebo.
Trial: NCT04357457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose 5% during 5 days
Trial: NCT00093873
Drug: Anti-angiogenesis
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenesis
Trial: NCT01231555
Drug: GSK2248761 100 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x100 mg capsule plus matching placebo
Trial: NCT03509220
Drug: PBK-1701TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive PBK-1701TC for colonoscopy.
Trial: NCT03509220
Drug: Standard oral preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive the standard oral preparation for colonoscopy
Trial: NCT00054665
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Trial: NCT00054665
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 day IV day 5 bolus. Repeat cycle every 21 days.
Trial: NCT00405444
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
Trial: NCT03233932
Drug: LeuplinⓡInj
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
Trial: NCT05233657
Drug: JX11502MA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT00669617
Drug: Placebo to salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to salbutamol delivered via MDDPI
Trial: NCT00003632
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04737473
Drug: Opiod Free Anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The OFA protocol will entailed induction of anesthesia intravenously by the administration of the following drugs: magnesium sulfate 40mg/kg (without exceeding 2.5g), lidocaine 1.5mg/kg, ketamine 25mg, propofol 1.5-2mg/kg, dexamethasone 8mg and rocuronium
Trial: NCT02723201
Drug: TAK-020 Captisol Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-020 solution.
Trial: NCT02723201
Drug: TAK-020 SDT
RxNorm normalized name: Equisul SDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-020 Solid dispersion tablet.
Trial: NCT02723201
Drug: TAK-020 IRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-020 immediate release tablet.
Trial: NCT02723201
Drug: TAK-020 Solid Formulation
RxNorm normalized name: CORYDALIS SOLIDA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-020 solid formulation
Trial: NCT01243112
Drug: 1% Lidocaine with Epinephrine (1:100,000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2ml Intradermal injection once.
Trial: NCT01243112
Drug: 0.25% Bupivacaine with Epinephrine (1:200,000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2ml Intradermal injection once.
Trial: NCT01243112
Drug: 1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2ml Intradermal injection once.
Trial: NCT01495247
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
Trial: NCT00375830
Drug: 99mTc-methyl diphosphonate
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabel for bone scan procedures
Trial: NCT03200496
Drug: TALION®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug : Talion®
Trial: NCT00010426
Drug: cysteamine hydrochloride
RxNorm normalized name: cysteamine hydrochloride
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01859377
Drug: V0498 - A mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oromucosal administration
Trial: NCT01507363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 7 days, starting on the day of surgery
Trial: NCT00236366
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01859377
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral administration
Trial: NCT03590912
Drug: Steroid Drug (prednisolone)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will be treated with steroid drugs. Oral prednisolone, 1 mg/kg body weight daily in two divided dose for 1 week followed by half mg/kg/day in two divided dose for next one week.
Trial: NCT01627587
Drug: GSK221149 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C: 100mg of GSK221149 single dose
Trial: NCT01627587
Drug: GSK221149 750 mg + Food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment E: 750 mg of GSK221149 administered with a high fat meal
Trial: NCT01448395
Drug: [14C]NXL104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg/100mL intravenous solution
Trial: NCT02085291
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion to titrate MAP to usual level
Trial: NCT03222427
Drug: [13C415N3] LY3314814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT02222714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
Trial: NCT02135835
Drug: Shenfu Zhusheye
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00858429
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
Trial: NCT01988103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet BID for 16 weeks
Trial: NCT01114529
Drug: Prograf or Neoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active CNI-based control (Prograf or Neoral)
Trial: NCT00592475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00440726
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2/day IV over 15 minutes on Day 1
Trial: NCT00440726
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Trial: NCT03634475
Drug: PP-001
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug - no placebo
Trial: NCT02040506
Drug: IGN523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
Trial: NCT01442259
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01648257
Drug: GSK1265744 Na Salt Tablets
RxNorm normalized name: ibuprofen, sodium salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
Trial: NCT01535079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration
Trial: NCT01535079
Drug: Ibuprofen 35 mg
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single administration
Trial: NCT01535079
Drug: Ibuprofen 25 mg
RxNorm normalized name: diphenhydramine-ibuprofen 25 mg-200 mg oral capsule
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single administration
Trial: NCT01535079
Drug: Ibuprofen 15 mg
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single administration
Trial: NCT01181479
Drug: AG200-15 (cycles 1-13)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG200-15 containing ethinyl estradiol and levonorgestrel
Trial: NCT00019071
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00143572
Drug: Magnesium Pidolate, Hydroxyurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
Trial: NCT01560702
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
Trial: NCT04625972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (× 2 IM injections) of saline placebo on Day 1.
Trial: NCT04483037
Drug: Bowklean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: assigned intervention
Trial: NCT01245062
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK inhibitor
Trial: NCT01245062
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator Choice of DTIC or paclitaxel
Trial: NCT03208452
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
Trial: NCT03362593
Drug: MEDI7219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Drug
Trial: NCT03362593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02940132
Drug: SC10914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC10914 will be administered orally.
Trial: NCT01269333
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 7 days
Trial: NCT00448032
Drug: PPM-204
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02482155
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 400 mg single dose oral solution
Trial: NCT04471337
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1817080 will be administered orally as tablet.
Trial: NCT04359511
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hémisuccinate d'hydrocortisone 3,5 mg/kg/jour (IV)
Trial: NCT00599417
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo controlled
Trial: NCT00616629
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT01653119
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
Trial: NCT02159027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
Trial: NCT05213988
Drug: Fibrates
RxNorm normalized name: Fibrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate 400 mg/day
Trial: NCT03472508
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Trial: NCT03472508
Drug: Enalapril Maleate and Folic Acid Tablets (Yiye)
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Trial: NCT04601909
Drug: FX-322
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active comparator
Trial: NCT01440920
Drug: OCV-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously administered once a week, 4 times at the dose of 0.3 mg
Trial: NCT01440920
Drug: OCV-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously administered once a week, 4 times at the dose of 1 mg
Trial: NCT01440920
Drug: OCV-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneously administered once a week, 4 times at the dose of 3 mg
Trial: NCT01379209
Drug: RGI-2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single administration of RGI-2001 on Day 0 post AHSCT.
Trial: NCT01379209
Drug: Calcineurin Inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Trial: NCT01379209
Drug: Conditioning Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
Trial: NCT01379209
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01379209
Drug: Mofetil Mycophenolate
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03850587
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparator medication
Trial: NCT03850587
Drug: Tramadol 37.5Mg+ Celecoxib 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental medication
Trial: NCT03850587
Drug: Tramadol 75mg+ Celecoxib 200mg
RxNorm normalized name: celecoxib / tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental medication
Trial: NCT03850587
Drug: Tramadol 150mg+ Celecoxib 200mg
RxNorm normalized name: celecoxib / tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental medication
Trial: NCT00517062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo self-injected once a day subcutaneously at bedtime.